Skip to main content

Table 4 Mean percent difference in BMD between affected and contralateral side in sarcoma patients

From: Early decrements in bone density after completion of neoadjuvant chemotherapy in pediatric bone sarcoma patients

    Mean (95% CI) Mean (95% CI) Mean (95% CI)
  Location n= aBMD (g/cm2) vBMD (g/cm3) BMC (g)
FN UpEx 10 -1.3 (-5.8 to 3.3) -3.2 (-10.2 to 3.9) 3.3 (-5.6 to 12.1)
  Femur/Tibia 22 -13.7 (-18.8 to -8.5) -12.7 (-20.1 to -5.3) -13.6 (-18.1 to -9.1)
  Pelvis/Fibula 7 -7.1 (-14.6 to 0.4) -6.2 (-13.8 to 1.5) -7.8 (-15.5 to 0.0)
Calc UpEx 8 -4.4 (-9.3 to 0.4)   -4.3 (-9.0 to 0.5)
  Femur/Tibia 19 -22.5 (-30.1 to -15.0)   -22.6 (-30.1 to -15.1)
  Pelvis/Fibula 6 -18.8 (-47.9 to 10.3)   -18.9 (-47.8 to 10.0)
  1. * Lower extremity sarcoma patients subgrouped into sarcomas within the vicinity of primary weight-bearing joints (femur/tibia) and pelvis/fibula.
  2. CI = confidence interval, aBMD = areal bone mineral density (g/cm 2 ), vBMD = volumetric bone mineral density (g/cm 3 ), BMC = bone mineral content (g), UpEx = Upper Extremity, FN =femoral neck, Calc = calcaneus